IQVIA Holdings Inc. $IQV Shares Sold by Markel Group Inc.

Markel Group Inc. reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 15.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,642 shares of the medical research company’s stock after selling 9,084 shares during the quarter. Markel Group Inc.’s holdings in IQVIA were worth $7,823,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Everpar Advisors LLC increased its position in IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 62 shares during the period. Private Trust Co. NA increased its position in shares of IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after purchasing an additional 67 shares during the period. Ballentine Partners LLC increased its position in shares of IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after purchasing an additional 69 shares during the period. Independent Advisor Alliance increased its position in shares of IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after purchasing an additional 72 shares during the period. Finally, Nemes Rush Group LLC increased its position in shares of IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 81 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IQV. Truist Financial lifted their price target on IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price target on IQVIA in a research report on Wednesday, September 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Finally, Evercore ISI lifted their price target on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Stock Performance

Shares of NYSE IQV opened at $218.26 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock has a market capitalization of $37.10 billion, a price-to-earnings ratio of 31.59, a PEG ratio of 2.39 and a beta of 1.32. The stock’s fifty day simple moving average is $195.48 and its 200 day simple moving average is $172.51. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $225.91.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.